Please assess the completion status of the following clinical trial:

Trial Title: Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 to 80~2. Diagnosis of moderately to severely active Crohn's disease (CD)~3. CD involvement of the ileum and/or colon~4. Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents, within protocol-specified parameters:~   1. Immunomodulators~  2. Tumor necrosis factor-alpha (TNFα) antagonists~  3. Corticosteroids~5. May be receiving a therapeutic dose of conventional therapies for irritable bowel disease (IBD) defined by the protocol~Exclusion Criteria~1. Evidence of abdominal abscess at the initial screening visit, other than a minimum of 10 aphthous ulcerations involving a minimum of 10 contiguous cm of intestine~2. Extensive colonic resection, subtotal or total colectomy~3. History of \>3 small bowel resections or diagnosis of short bowel syndrome~4. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine~5. Have received non permitted IBD therapies within either 30 or 60 days, depending on the medication, as stated in the protocol~6. Chronic hepatitis B or C infection~7. Active or latent tuberculosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vedolizumab (Type: EXPERIMENTAL): In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase.
- Placebo (Type: PLACEBO_COMPARATOR): In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.

Based on this trial design, predict the completion outcome and termination type (if applicable).